SQUARE
e-

SQUARE

 
Healthcare online Keeping you up-to-date
VOL.  22     ISSUE:  7    July 2024 Medical Services Department

SQUARE Pharmaceuticals PLC.

Features

EDITORIAL TEAM

OMAR AKRAMUR RAB

MBBS, FCGP, FIAGP,

P G Dip. Business Management

Rubyeat Adnan

MBBS, MPH

Moshfiqur Rahman

MBBS

EDITORIAL

Dear Doctor:

Welcome to our healthcare bulletin 'e-SQUARE' !

Our current issue focused on some interesting features like

"Combination Diabetes Drugs !", "CVD Benefits !", "Breast Cancer !", "Parkinson's Disease !", "Epilepsy Medications !", "Migraine Relief !".

In our regular feature, we have some products information of SQUARE Pharmaceuticals PLC. as well.

We always appratiate your feedback !

Click on to reply mode.

Yours sincerely,

 

Editorial Team

Reply Mode      : e-square@squaregroup.com

The views expressed in this publication do not necessarily reflect those of its editor or SQUARE PHARMACEUTICALS PLC.

Combination Diabetes Drugs !

Combination diabetes drugs offers complementary heart and kidney benefits

New research shows combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to offer additional protection against heart and kidney disease in patients with diabetes. SGLT2is, also called gliflozins, are a class of drug that lower blood glucose by increasing its excretion in the urine, while GLP-1RAs, such as Ozempic, work by enhancing insulin release and sensitivity. Both classes of medicine have each been shown to improve cardiovascular outcomes. Although small, relatively short-term trials have suggested that using these medicines together improves blood glucose control, their combined effects on heart disease and kidney failure are less clear. Researchers involved in the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists' Consortium (SMART-C) pooled data across 12 large-scale, placebo-controlled trials of SGLT2is involving 73,238 patients with diabetes, 3,065 of whom were already receiving GLP1-RAs. The meta-analysis showed that the benefits of SGLT2is were observed independent of GLP1-RA use. SGLT2is reduced the risk of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death) by 11% and hospitalization for heart failure or cardiovascular death by 23% versus placebo, even when added to GLP1-RAs. SGLT2is also reduced the risk of chronic kidney disease progression by 33% when added to GLP1-RAs and slowed the annual loss of kidney function by almost 60% when added to GLP-1RAs. No new safety concerns were identified when SGLT2is and GLP-1RAs were used in combination. Both classes of medicines work independently of each other. SGLT2 inhibitors have clear protective effects against heart failure and chronic kidney disease, while GLP-1 receptor agonists can reduce the risk of heart attack, stroke, and also kidney disease as recently demonstrated in the landmark FLOW trial. The findings support using this combination to further improve outcomes in patients with type 2 diabetes who meet guideline recommendations for both therapies. Diabetes is a known risk factor for cardiovascular and kidney disease, with impaired glucose control causing damage to blood vessels in the heart and kidneys. Many patients with diabetes live with cardiovascular disease or chronic kidney disease, with prevalence increasing in the years following a diabetes diagnosis.

SOURCE: George Institute for Global Health, July, 2024

Return to top

 CVD Benefits !

Palliative care beneficial to improve quality of life with CVD

Implementing patient-centered palliative care therapies, including prescribing, adjusting or discontinuing medications as needed, may help control symptoms and improve quality of life for people with heart disease, according to "Palliative Pharmacotherapy for Cardiovascular Disease. The new scientific statement reviews current evidence on the benefits and risks of cardiovascular and essential palliative medications. The statement provides guidance for health care professionals to incorporate palliative methods as part of holistic medication management at all stages of a patient's health conditions, emphasizing the importance of shared decision-making and goal-oriented care. Palliative care is specialized medical care that aims to relieve symptoms and enhance quality of life for people experiencing health-related issues due to serious illnesses. This approach may benefit patients with cardiovascular disease, including coronary heart disease, valvular heart disease, pulmonary arterial hypertension and heart failure. These conditions significantly reduce quality of life, require ongoing treatment, are usually progressive and are associated with high mortality rates. The progression of many conditions, from chronic to advanced and end-stage, may be unpredictable and marked by worsening symptoms that result in recurrent hospitalization. Palliative care complements standard cardiovascular care by reducing physical symptoms, managing emotional distress and assisting patients in making decisions that coincide with their goals of care. A palliative approach can be integrated into the medication management of patients at any stage of heart disease, from chronic, stable heart disease to advanced and end-stage cardiovascular disease. And, importantly, palliative care supports a more goal-oriented, patient-centered approach to treatment. Previous studies have found that adding palliative care interventions to evidence-based care improved patients' quality of life, functional status, depression, anxiety and spiritual well-being and reduced the risk of hospital readmission for patients with advanced heart disease compared to clinical care alone. Despite these benefits, fewer than 20% of people with end-stage heart disease receive palliative care. In addition, People with heart failure who are referred to palliative care are predominantly white, have higher socioeconomic status and are more likely to receive care at academic medical centers. To achieve these goals, cardiovascular medications that provide symptom relief, such as diuretics to manage fluid retention in heart failure, should be prioritized in patients with advanced heart disease. Adding palliative medicines to evidence-based cardiovascular therapies can be complementary to manage symptoms and optimize quality of life. Examples of common palliative medicines include antidepressants, opioids for pain relief and difficulty breathing, and anti-nausea medications.

SOURCE: American Heart Association, July 2024

Return to top

 
 
Breast Cancer !

 Promising approach to prevent recurrence of breast cancer

Treatment outcomes for breast cancer have become better over the years, but proportion of breast cancers still recur even after long periods without signs of cancer remaining dormant in the body. Cancer researchers discovered a mechanism that wakes up these dormant breast cancer cells and demonstrated that preventing the mechanism can significantly improve treatment outcomes in experimental models. Although treatment outcomes for breast cancer have significantly improved through new research-based therapies, it remains the second most common fatal cancer in women. A particular challenge in breast cancer treatment is the recurrence of the disease. Even when treatment appears to be successful and the cancer is considered gone, it can return years later either locally or, in the worst case, by spreading to other parts of the body, such as the brain. The reasons why dormant breast cancer cells awake even after several years are not well understood. However, identifying these reasons could provide an opportunity to develop new therapies to prevent cancer recurrence. DUSP6 (Dual specificity phosphatase 6) protein activity associated with awakening of the breast cancer cells. Treating breast cancer cells sensitive to treatment with HER2 (Human epidermal growth factor receptor) inhibitor for nine months and by monitoring how these cancer cells were able to restart their growth during the treatment. By sequencing the molecular changes in the cells, the group identified the DUSP6 protein, whose expression closely followed the development of therapy resistance. The activity of the DUSP6 protein was blocked during cancer treatment, breast cancer cells lost their ability to grow. Blocking the protein also made the previously treatment-resistant cancer cells more sensitive to HER2 inhibitors. Another important finding was that by inhibiting DUSP6, it was possible to slow the growth of breast cancer metastases in the brain in mouse models. The significance of the study is highlighted by the group's access to experimental drug molecules that inhibit the DUSP6 protein. By administering the drug, the researchers demonstrated that the protein could be inhibited in mice without significant side effects. Importantly, the drug was shown to significantly enhance the therapeutic effect of several existing HER2 inhibitors.

SOURCE: Science Daily News, July, 2024

Return to top

 
 
Parkinson's Disease !

Blood test could predict Parkinson's seven years before symptoms

Scientists have developed a simple blood test that uses artificial intelligence (AI) to predict Parkinson's up to seven years before the onset of symptoms. Parkinson's disease is the world's fastest growing neurodegenerative disorder and currently affects nearly 10 million people across the globe. The condition is a progressive disorder that is caused by the death of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine, due to the build-up of a protein alpha-synuclein. Currently, people with Parkinson's are treated with dopamine replacement therapy after they have already developed symptoms, such as tremor, slowness of movement and gait, and memory problems. But researchers believe that early prediction and diagnosis would be valuable for finding treatments that could slow or stop Parkinson's by protecting the dopamine producing brain cells. The research, published in Nature Communications, found that when a branch of AI called machine learning, analysed a panel of eight blood based biomarkers whose concentrations are altered in patients with Parkinson's, it could provide a diagnosis with 100% accuracy. The team then experimented to see whether the test could predict the likelihood that a person would go on to develop Parkinson's. Analysing blood from 72 patients with Rapid Eye Movement Behaviour Disorder (iRBD). This disorder results in patients physically acting out their dreams without knowing it (having vivid or violent dreams). It is now known that about 75-80% of these people with iRBD will go on to develop a synucleinopathy (a type of brain disorder caused by the abnormal buildup of a protein called alpha-synuclein in brain cells) -- including Parkinson's. When the machine learning tool analysed the blood of these patients it identified that 79% of the iRBD patients had the same profile as someone with Parkinson's. The patients were followed up over the course of ten years and the AI predictions have so far matched the clinical conversion rate with the team correctly predicting 16 patients as going on to develop Parkinson's and being able to do this up to seven years before the onset of any symptoms. The team are now continuing to follow up on those predicted to develop Parkinson's, to further verify the accuracy of the test.

SOURCE: Science Daily News, July 2024

Return to top

 

 
Epilepsy Medications !

Do Epilepsy medications taken during pregnancy affect a child's creativity

While older drugs for epilepsy, taken while pregnant, have been shown in previous research to affect the creative thinking of children, a new study finds no effects on creativity for children born to those taking newer epilepsy drugs. Researchers looked only at children with higher concentrations of these medications in the mother's blood during the third trimester, the study found an association with poorer performance in tests of children's executive function, but no effect on their creative abilities. The findings highlight that even for epilepsy medications that are generally considered to be safe in pregnancy, dose adjustments should be made with a goal of reaching an optimal balance between controlling seizures and the minimizing negative effects on the developing child. The study involved 251 children of female participants with epilepsy and 73 children of female participants without the disease. Of those with epilepsy, most were taking just one epilepsy medication. Of this group, 81 people were on lamotrigine and 68 people were on levetiracetam. The children were evaluated at age four and a half with a test of creative thinking where they were provided with a shape or figure and responded by completing or adding their own illustrations. This test assesses fluency, flexibility and originality abilities. After adjusting for mothers' IQ and education, researchers found no differences in the creativity scores between the children born to mothers with epilepsy and those born to mothers without the disease. In addition, they found no differences in creativity between the children of mothers with epilepsy that could be linked to different levels of antiseizure medications found in mothers' blood samples during the third trimester. However, researchers found higher third trimester blood concentrations of these medications were associated with poorer performance on tests of executive skills. This link was mainly associated with exposure to levetiracetam. There is still so much to learn about the impact of a mother's epilepsy medications on their child's creative development. More studies are needed, especially in older children, to assess the full effect of these medications on childhood development.

SOURCE: Science Daily News, July 2024

Return to top

 
 
Migraine Relief !

 Hallmark of anti-migraine treatments

By discovering a potential new cellular mechanism for migraines researchers have found a new way to treat chronic migraine. They explained that the dynamic process of routing and rerouting connections among nerve cells, called neural plasticity, is critical to both the causes and cures for disorders of the central nervous system such as depression, chronic pain, and addiction. The structure of the cell is maintained by its cytoskeleton which is made up of the protein, tubulin. Tubulin is in a constant state of flux, waxing and waning to change the size and shape of the cell. This dynamic property of the cell allows the nervous system to change in response to its environment. Tubulin is modified in the body through a chemical process called acetylation. When tubulin is acetylated it encourages flexible, stable cytoskeleton; while tubulin deacetylation induced by histone deacetylase 6, or HDAC6, promotes cytoskeletal instability. Studies show that decreased neuronal complexity may be a feature, or mechanism, of chronic migraine. Restoration of this complexity could be a hallmark of anti-migraine treatments. Blocking HDAC6 would allow neurons to restore its flexibility so the brain would be more receptive to other types of treatment. When HDAC6 is inhibited, tubulin acetylation and cytoskeletal flexibility is restored. Additionally, HDAC6 reversed the cellular correlates of migraine and relieved migraine-associated pain, according to the study. Once out of the cycle of decreased neuronal complexity, the brain may become more responsive to pain management therapies.

SOURCE: Science Daily News, July 2024

Return to top

 
 

New Products of SQUARE Pharmaceuticals PLC.

  Product Glympa TM
  Generic Name Empagliflozin & Linagliptin
  Strength 10/ 5 mg & 25/5 mg
  Dosage form Tablet
  Therapeutic Category Oral Antidiabetic Preparation
  Product Fliban TM  
Generic Name Flibanserin
Strength 100 mg
Dosage form Tablet
Therapeutic Category Sexual Dysfunction
  Product Sopilax TM
  Generic Name Sodium Picosulfate
Strength 10 mg
  Dosage form Tablet & Oral Solution
  Therapeutic Category Laxative

Return to top

 

Copyright © 2024 SQUARE Pharmaceuticals PLC. All rights reserved